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Experimental Manipulations to Test
Theory-Driven Mechanisms of
Cognitive Behavior Therapy
Matthew W. Southward*† and Shannon Sauer-Zavala †
Department of Psychology, University of Kentucky, Lexington, KY, United States
Despite decades of randomized-controlled trials demonstrating the efficacy of
cognitive-behavior therapy (CBT), the mechanisms by which CBT achieves its effects
remain unclear. Here, we describe how one adaptive intervention, the sequential multiple
assignment randomized trial (SMART), can be used to randomize patients at multiple
decision points in treatment to draw stronger causal claims about mechanisms unfolding
in the course of CBT. We illustrate this design using preliminary data and case examples
from an ongoing SMART in which we are testing the role of aversive reactions to negative
emotions as a hypothesized mechanism of change in the Unified Protocol. Finally, we
address common concerns with SMARTs and highlight howmechanistic research serves
to personalize and optimize the delivery of CBT.
Keywords: cognitive behavior therapy (CBT), mechanism, SMART, personalization, unified protocol (UP)
INTRODUCTION
Hundreds of randomized controlled trials (RCTs) have shown that cognitive behavior therapies
(CBTs) are efficacious for many psychiatric conditions (1–3). RCTs are the optimal experimental
design to test the efficacy of a treatment relative to comparison conditions. Randomly assigning
patients to condition (e.g., CBT vs. waitlist) provides confidence that any post-treatment differences
between conditions are due to the effects of the intervention(s), rather than patient characteristics
or other confounding variables. RCTs for psychological treatments, particularly CBTs, were
especially informative following DSM-III (4), which included more reliable symptom criteria for
each psychiatric disorder. These criteria allowed researchers to conduct RCTs to assess how well
CBTs addressed specific constellations of symptoms, relative to other treatment conditions.
Given the established efficacy of many CBTs (5), there has been an increased push to characterize
which mechanisms drive symptom improvement [e.g., (6)]. Mechanisms of change are defined as
“. . . core psychological and biological processes . . . [that] explain specifically how characteristics
of the dysfunction are altered by the intervention and how that translates to symptom change”
[(7), p. 87]. The relations among treatments, associated therapeutic mechanisms, and symptom
change has often been explored statistically, whereby a mediator variable accounts for the relation
between an intervention and an outcome (8–11). However, to determine whether a particular
process constitutes a mechanism of symptom reduction, rather than simply a statistical mediator,
several criteria must be met. These criteria include: (a) a strong association between the mechanism
of action and the outcome, (b) temporal precedence where change in the mechanism precedes
change in the outcome, (c) manipulating levels of the mechanism to determine how they relate to
outcomes, and (d) a dose-response relation such that greater change in a mechanism leads to better
outcomes (7, 9, 10).
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Treatment researchers have made great strides toward
identifying mechanisms of CBTs by utilizing more
intensive measurements (e.g., at each session rather than
only pre- and post-treatment). Frequent measurement
of candidate mechanisms and psychiatric symptoms can
provide evidence for criteria (a) and (b) for establishing a
therapeutic mechanism. However, even when researchers
statistically determine temporal precedence, results remain
observational and can at best reveal Granger causality (12),
which indicates that a temporally-lagged variable (Xt−1)
explains unique variance in another variable at the next
timepoint (Yt) above and beyond previous observations of that
variable (Yt−1).
To draw stronger causal conclusions about the processes
driving therapeutic improvements, it is necessary to apply
innovative research designs that leverage the advantages
of random assignment. We argue that sequential multiple
assignment randomized trials [SMARTs; (13)], a type of
multi-stage, experimental design developed for adaptive
interventions, are an elegant way to evaluate treatment effects
and mechanisms within a single clinical trial. We will first
provide an overview of SMARTs and then describe how they
can be adapted to evaluate the hypothesized mechanism
of an intervention. We will present illustrative data from
a SMART we are currently conducting to highlight how
this design can provide a stringent, experimental test of
core mechanisms.
SEQUENTIAL MULTIPLE ASSIGNMENT
RANDOMIZED TRIALS (SMARTS)
SMARTs are a framework for evaluating adaptive interventions
in clinical trials. In contrast to traditional RCTs that involve
one primary clinical decision (e.g., randomizing a patient
to the treatment or control condition), SMARTs contain
multiple randomizations. For example, Chronis-Tuscano et al.
(14) conducted a SMART to characterize best practices for
families in which mothers and their children exhibit ADHD
symptoms. In the initial randomization, mothers received
stimulant medication or behavioral training to test which
treatment approach is relatively more efficacious to start with.
The second randomization occurred 8 weeks later; patients
were randomized to either continue initial treatment or receive
the alternative intervention as a supplement to their initial
treatment. Because patients are randomized to receive treatment
adaptations, SMARTs enable researchers to draw stronger
conclusions about optimal treatment planning decisions.
In addition to randomizations based solely on time (e.g., re-
randomizing all patients at session eight), researchers may also
use tailoring variables to determine whether to adapt treatment.
For instance, patients whose anxiety symptoms do not a reach a
pre-determined threshold by a particular point in treatment may
be re-randomized to continue with current care or receive more
intensive treatment.
EVALUATING MECHANISMS OF ACTION
USING SMARTS
Researchers implementing SMART designs are not limited to
using symptoms as tailoring variables. In fact, we argue that
to test hypothesized mechanisms of change in CBT, researchers
should use the engagement of these mechanisms to guide
treatment decision-making. Because changes in mechanisms
should precede symptom changes, improvement in hypothesized
mechanisms may represent an early indicator of eventual
response. In this section, we describe the design of a pilot
SMART we are currently conducting to evaluate methods
for personalizing the delivery of the Unified Protocol [UP;
(15)], an efficacious transdiagnostic CBT for a variety of
psychiatric disorders (16, 17). In our initial randomization,
patients with primary anxiety, depressive, or related disorders
without imminent suicidal ideation are randomized to receive
the modules (i.e., skills) from the UP in a personalized or
standardized order. The second stage randomization occurs at
mid-treatment (i.e., after 6 sessions), with patients assigned to
either discontinue care immediately or receive the remaining
six sessions. Patients randomized to discontinue immediately
are sent weekly symptom measures to track their progress
and are offered referrals as requested at the Week 12 follow-
up assessment.
The developers of the UP have articulated a functional
model of mood, anxiety, and related disorders in which
these disorders are maintained by the transaction of frequent
negative emotions (i.e., neuroticism) and aversive reactions to
these emotions (18, 19). Aversive reactions may take many
forms, including experiential avoidance, emotional suppression,
worry, rumination, or distraction – any behavior used to
escape or distract from one’s emotions. Recent evidence
suggests that reductions in certain forms of aversive reactions
(e.g., experiential avoidance, anxiety sensitivity) precede and
predict reductions in anxiety symptoms in CBT [(20–25);
cf. (26)]. To measure aversive reactivity, participants in our
SMART are completing the Distress Aversion subscale of
the Multidimensional Experiential Avoidance Questionnaire
[MEAQ-DA; (27)] before every weekly therapy session. The
MEAQ-DA is a 13-item self-report measure designed to assess
negative evaluations of and attitudes toward distress that has
demonstrated good internal consistency across clinical samples
(23, 27). The MEAQ-DA is sensitive to change in response to
CBT for anxiety disorders [d = 0.82; (23)] and scores can range
from 13–78.
We contend that our SMART design and, in particular,
our secondary randomization (i.e., early termination vs. full
course of care) are well-suited to evaluate aversive reactivity as
a mechanism of change in the UP. The burgeoning evidence
across independent treatment studies suggests the UP leads
to changes in aversive reactivity. Variability in these changes
indicate the degree to which the UP naturalistically manipulates
different levels of this mechanism. Because patients are then
randomized to receive 6 or 12 sessions, we can determine
the degree to which aversive reactivity must improve in
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early sessions to predict maintenance or continued symptom
improvement for patients who terminate at mid-treatment.
Adequate symptom reduction at week 12 follow-up in patients
who discontinue after six sessions and demonstrate mechanism
engagement provides clear evidence for the importance of
targeting aversive reactivity. However, unlike symptommeasures,
which have established threshold scores to determine patient
progress, “mechanism engagement” for aversive reactivity has
not been operationally defined. Thus, thresholds indicating
the degree of change in mechanisms that predicts continued
symptom improvement must first be established for measures
of hypothesized mechanisms of treatment. Our current SMART
will allow us to operationally define adequate target engagement
of aversive reactivity as measured by the MEAQ-DA, allowing
us to use these results to define the bounds of a tailoring
variable in subsequent SMARTs. Randomizing patients to
discontinue treatment after achieving a pre-specified cutoff
for target engagement provides a more stringent test of
whether candidate mechanisms are associated with downstream
symptom improvement.
In the following section, we will present illustrative data
from this trial as an example of how to establish target
engagement thresholds by examining: (a) variability in MEAQ-
DA scores; (b) whether early session changes in MEAQ-DA
scores precede later session symptom changes; and (c) the
magnitude of change on MEAQ-DA scores needed in early
sessions to predict maintenance or continued improvement in
symptoms for patients who terminate at mid-treatment.
Variability in Hypothesized Mechanisms
Variability in our hypothesized mechanism, MEAQ-DA scores,
is assessed in two ways: within each decision point and from one
decision point to the next. Variability within a decision point is
necessary to ensure that all participants would not be assigned to
the same decision condition. If all patients had the same MEAQ-
DA scores at mid-treatment, we would not be able to use this
variable to make discontinuation decisions. Variability from one
decision point to the next is necessary, in this case, to ensure the
hypothesized mechanisms of change are themselves responsive
to the study treatment. In our sample to date (n = 46), we have
found substantial variability at both pre- (M= 45.00, SD= 11.06)
and mid-treatment (M = 36.57, SD = 13.63) in the MEAQ-
DA. Further, MEAQ-DA scores significantly decreased from pre-
to mid-treatment, t(45) = −5.30, p < 0.01, 95% CI [−11.64,
−5.23]. It is important to note, however, that without a control
comparison group, these changes may, to some extent, indicate
participant regression to the mean.
Changes in Mechanisms Preceding
Symptom Change
We selected the Overall Anxiety Severity and Impairment Scale
[OASIS; (28)] as our measure of symptoms. Like the MEAQ-
DA, the OASIS was administered at pre-, mid-, and post-
treatment. In preliminary analyses of relatively smaller samples,
it can be useful to determine the proportion of the sample for
whom changes in hypothesized mechanisms precede changes
in symptoms. Decreases in MEAQ-DA scores from pre- to
mid-treatment preceded decreases in OASIS scores from mid-
to post-treatment for 18 participants (39%) and increases in
OASIS scores for 9 participants (20%). Similarly, decreases in
OASIS scores from pre- to mid-treatment preceded decreases
in MEAQ-DA scores for 20 participants (43%). These findings
suggest that reductions inMEAQ-DA scores tend to precede later
anxiety symptom improvements and not deterioration, although
anxiety symptom improvement may also precede mechanism
change for a substantial number of participants. Although these
preliminary results provide mixed evidence for aversive reactivity
as the sole mechanism of action in the UP, they demonstrate
(a) the importance of comparing alternative hypotheses in the
same study (10) and (b) the potential to identify moderators
to distinguish the patients for whom aversive reactivity or
anxiety symptoms function as mechanisms of change. When
possible, researchers conducting experimental manipulations of
treatment mechanisms should include competing experimental
conditions or measures of alternative mechanisms, as in our
SMART, that can be compared to researchers’ primary theorized
mechanism to provide a more stringent and comprehensive test
of the hypothesis.
Degree of Engagement in Hypothesized
Mechanisms
Determining how much change is needed to consider a
hypothesized mechanism engaged remains an open question.
Researchers may choose relatively conservative but standardized
metrics such as the reliable change index (29) as the standard
of mechanism engagement. Alternatively, they may estimate
the degree of change preceding certain symptom outcomes in
one sample and apply this estimate to an independent hold-
out sample. Given the preliminary stage of our study, we will
highlight three exemplar cases of mechanism engagement and
downstream clinical outcomes.
Patient 1
Patient 1 is a 61-year-old White female with primary generalized
anxiety disorder (GAD) and specific phobia. She received UP
modules in the standard order and discontinued treatment after
six sessions. Thus, Patient 1 received the modules Understanding
Emotions (UE), Mindful Emotion Awareness (MEA), and
Cognitive Flexibility (CF; 2 sessions each) before discontinuing
treatment. She demonstrated reliable change (Reliable Change
Index [RCI] = −2.68) in MEAQ-DA scores from pre-treatment
(46) to end-of-treatment (EOT; 30). However, she reported only
a 1-point decrease in OASIS scores from pre-treatment (6) to
EOT (5). Six weeks after treatment discontinuation, she reported
a 40% decrease in anxiety severity (OASIS = 3; Figure 1A). This
pattern of data suggests that achieving reliable change on the
MEAQ-DA may predict continued symptom improvement even
after treatment is withdrawn.
Patient 2
Patient 2 is a 45-year-old Arab-American male with primary
social anxiety disorder and GAD. He received UP modules in a
personalized order and completed the full course of treatment.
Thus, he received the modules Counting Emotional Behaviors
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FIGURE 1 | (A) Patient 1 MEAQ-DA and OASIS data demonstrating decreases in MEAQ-DA scores from pre-treatment (PreTx) to end-of-treatment (EOT) and
subsequent decreases in OASIS scores following treatment discontinuation from EOT to post-treatment (Post-Tx). (B) Patient 2 MEAQ-DA and OASIS data
demonstrating greater decreases in MEAQ-DA scores from Pre-Tx to mid-treatment (Mid-Tx) followed by greater subsequent decreases in OASIS scores from Mid-Tx
to EOT. (C) Patient 3 MEAQ-DA and OASIS data demonstrating decreases in OASIS scores from Pre-Tx to EOT without corresponding decreases in MEAQ-DA
scores, followed by a return to Pre-Tx OASIS scores by Post-Tx.
(CEB) and UE in the first six sessions and MEA, CF, and
Confronting Physical Sensations (CPS) in the last six sessions. He
demonstrated reliable change on the MEAQ-DA (RCI = −5.35)
from pre- (51) tomid- (19) treatment. Similar to Patient 1, Patient
2 demonstrated almost no change in anxiety severity from pre-
(OASIS = 11) to mid- (OASIS = 10) treatment. Instead, after
six more sessions, he also reported a 50% decrease in anxiety
severity (OASIS = 5) at EOT (Figure 1B). Of course, because
Patient 2 continued to attend sessions after he achieved reliable
change on the MEAQ-DA, it is difficult to discern whether his
symptoms would have continued to improve if treatment had
been discontinued after session 6.
By contrast, some patients demonstrate symptom
improvement before mechanism engagement. In traditional
SMARTs that rely on symptom changes to make clinical
decisions, this may indicate a patient is a good candidate for
treatment discontinuation. However, symptom improvement
without corresponding mechanism engagement may not be
as durable.
Patient 3
Patient 3 is a 33-year-old White female with primary GAD
and body dysmorphic disorder. She received UP modules
in a personalized order and discontinued treatment after
six sessions. Thus, she received the CEB and CPS modules.
She demonstrated substantial improvement in anxiety severity
from pre- (OASIS = 13) to mid-treatment (OASIS = 7).
However, her MEAQ-DA scores were little changed from pre-
(36) to mid- (35) treatment (RCI = −0.17). Six weeks after
treatment discontinuation, Patient 3 reported anxiety scores
similar to pre-treatment (OASIS = 12), suggesting her symptom
gains in treatment were not as durable (Figure 1C). This
pattern of results suggests that changes in aversive reactivity
to emotions may be an important therapeutic mechanism in
the UP.
Of course, these are illustrative cases selected to
demonstrate how our second-stage randomization (i.e.,
discontinue after 6 sessions or continue for 12 sessions)
can be used to examine aversive reactivity as a mechanism
of symptom improvement. Data from our full sample will
allow us to establish the degree to which MEAQ-DA scores
must improve to predict continued symptom reduction
among participants randomized to discontinue treatment
early. These data will be used to establish the thresholds
necessary to use MEAQ-DA scores as a tailoring variable in
future projects.
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DISCUSSION
As researchers and funding agencies shift from evaluating
treatment outcomes to understanding the mechanisms by
which treatments function, innovative trial designs are
necessary. In particular, SMARTs allow for experimental
manipulation of mechanisms within efficacy or effectiveness
trials. Here, we have illustrated how our current SMART
enables us to answer hypotheses about the timing and degree
of change in a hypothesized mechanism needed for continued
symptom improvement following treatment discontinuation. By
examining different characteristics of mechanisms in treatment
(e.g., variability, timing relative to symptom change, and degree
of engagement), researchers can better characterize replicable
and actionable mechanisms that can ultimately lead to more
targeted interventions.
We have highlighted one current limitation of mechanistic
SMARTs, namely the lack of a consensus definition of mechanism
engagement. We believe this is appropriate, given the relatively
nascent state of this research. However, it is essential that
researchers first identify likely transtheoretical mechanisms
of change and assess the degree of change necessary for a
mechanism to be considered “engaged” by a patient. This
degree of change will likely involve a range of values that vary
based on individual differences, so we encourage researchers to
pool resources when possible to collect these data. A second
common limitation of SMARTs is the sample size needed to
provide adequate statistical power. Given even two levels of
randomization, it may appear that the sample sizes needed
would be impossibly large. However, as Almirall et al. (30)
note, researchers are rarely interested in testing differences
among all randomization combinations. Instead, researchers
should pre-specify which comparisons are of most interest and
calculate the necessary sample size based on these comparisons.
For instance, in our study, one comparison we will make is
between participants randomized to continue or discontinue
treatment, regardless of whether they received a personalized
or standardized order of UP modules. Because we expect
treatment discontinuation to exert a larger effect on outcomes
than module ordering, we will collapse across participants in the
personalization and standardization conditions to maximize our
statistical power. Practically, we encountered no limitations in
recruitment for this SMART, likely because all patients received
some treatment immediately. We are currently replicating this
study in a communitymental health clinic to test the acceptability
of discontinuing treatment to real-world providers, as thismay be
another limitation of SMARTs with treatment discontinuation.
We content that adaptive interventions, such as SMARTs,
offer a promising way to personalize and optimize CBT.
By characterizing which mechanisms are engaged by which
treatment processes, how much change is needed in these
mechanisms for a given patient, and when treatment can
be reliably discontinued, these experimental designs can
have a substantial influence on our understanding of core
mechanisms of action in treatment. Rather than relying solely
on symptom changes, which may be an unreliable indicator of
progress, researchers can leverage experimental manipulations of
treatment mechanisms to identify measures that clinicians can
incorporate relatively easily into their practice to enhance the
efficacy, efficiency, and accessibility of CBT (31).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by University of Kentucky Nonmedical Institutional
Review Board. The patients/participants provided their written
informed consent to participate in this study. Written informed
consent was obtained from the individual(s) for the publication
of any potentially identifiable images or data included in
this article.
AUTHOR CONTRIBUTIONS
MS performed the data analysis and drafted the manuscript.
SS-Z provided critical revisions. Both authors developed the
manuscript concept, study design, collected the preliminary
data, and approved the final version of the manuscript
for submission.
REFERENCES
1. Carpenter JK, Andrews LA,Witcraft SM, PowersMB, Smits JAJ, Hofmann SG.
Cognitive behavioral therapy for anxiety and related disorders: ameta-analysis
of randomized placebo-controlled trials. Depress Anxiety. (2018) 35:502–14.
doi: 10.1002/da.22728
2. Cristea IA, Gentili C, Cotet CD, Palomba D, Barbui C, Cuijpers
P. Efficacy of psychotherapies for borderline personality disorder: a
systematic review and meta-analysis. JAMA Psychiatry. (2017) 74:319–28.
doi: 10.1001/jamapsychiatry.2016.4287
3. Cuijpers P, Karyotaki E, Weitz E, Andersson G, Hollon SD, van Straten A.
The effects of psychotherapies for major depression in adults on remission,
recovery and improvement: a meta-analysis. J Affect Disord. (2014) 159:118–
26. doi: 10.1016/j.jad.2014.02.026
4. American Psychiatric Association (1980).Diagnostic and Statistical Manual of
Mental Disorders. 3rd ed. Washington, DC: Author.
5. David D, Cristea IA, Hofmann SG. Why cognitive behavioral therapy is
the current gold standard of psychotherapy. Front Psychiatry. (2018) 9:4.
doi: 10.3389/fpsyt.2018.00004
6. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn
K, et al. Research domain criteria (RDoC): toward a new
classification framework for research on mental disorders. Am
J Psychiatry. (2010) 167:748–51. doi: 10.1176/appi.ajp.2010.0909
1379
7. Kazdin AE. Moderators, mediators, and mechanisms of change in
psychotherapy. In: Lutz W, Knox S, editors. Quantitative and Qualitative
Methods in Psychotherapy. East Sussex: Routledge (2014). p. 87–101.
doi: 10.4324/9780203386071-6
Frontiers in Psychiatry | www.frontiersin.org 5 December 2020 | Volume 11 | Article 603009
Southward and Sauer-Zavala Experimental Manipulations of CBT Mechanisms
8. Alsubaie M, Abbott R, Dunn B, Dickens C, Keil TF, Henley W, et al.
Mechanisms of action in mindfulness-based cognitive therapy (MBCT) and
mindfulness-based stress reduction (MBSR) in people with physical and/or
psychological conditions: a systematic review. Clin Psychol Rev. (2017) 55:74–
91. doi: 10.1016/j.cpr.2017.04.008
9. Kazdin AE. Mediators and mechanisms of change in
psychotherapy research. Annu Rev Clin Psychol. (2007) 3:1–27.
doi: 10.1146/annurev.clinpsy.3.022806.091432
10. Kazdin AE. Understanding how and why psychotherapy leads to change.
Psychother Res. (2009) 19:418–28. doi: 10.1080/10503300802448899
11. Lorenzo-Luaces L, German RE, DeRubeis RJ. It’s complicated: the relation
between cognitive change procedures, cognitive change, and symptom change
in cognitive therapy for depression. Clin Psychol Rev. (2015) 41:3–15.
doi: 10.1016/j.cpr.2014.12.003
12. Granger CWJ. Investigating causal relations by econometric models and
cross-spectral models. Econometrica. (1969) 37:424–38. doi: 10.2307/1912791
13. Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A “SMART” design for
building individualized treatment sequences. Annu Rev Clin Psychol. (2012)
8:21–48. doi: 10.1146/annurev-clinpsy-032511-143152
14. Chronis-Tuscano A, Wang CH, Strickland J, Almirall D, Stein MA.
Personalized treatment of mothers with ADHD and their young at-risk
children: a SMART pilot. J Clin Child Adolesc Psychol. (2016) 45:510–21.
doi: 10.1080/15374416.2015.1102069
15. Barlow DH, Sauer-Zavala S, Farchione TJ, Murray Latin H, Ellard KE,
Bullis JR, et al. Unified Protocol for Transdiagnostic Treatment of Emotional
Disorders. 2nd ed. New York, NY: Oxford University Press (2018).
doi: 10.1093/med-psych/9780190686017.001.0001
16. Cassiello-Robbins C, Southward MW, Wilner Tirpak J, Sauer-Zavala S. A
systematic review of Unified Protocol applications with adult populations:
facilitating widespread dissemination via adaptability.Clin Psychol Rev. (2020)
78:101852. doi: 10.1016/j.cpr.2020.101852
17. Sakiris N, Berle D. A systematic review and meta-analysis of the Unified
Protocol as a transdiagnostic emotion regulation based intervention. Clin
Psychol Rev. (2019) 72:101751. doi: 10.1016/j.cpr.2019.101751
18. Bullis JR, Boettcher H, Sauer-Zavala S, Farchione TJ, Barlow DH. What
is an emotional disorder? A transdiagnostic mechanistic definition with
implications for assessment, treatment, and prevention. Clin Psychol Sci Pract.
(2019) 26:e12278. doi: 10.1111/cpsp.12278
19. Sauer-Zavala S, Wilner JG, Barlow DH. Addressing neuroticism in
psychological treatment. Personal Disord Theory Res Treat. (2017) 8:191–8.
doi: 10.1037/per0000224
20. Dalrymple KL, Herbert JD. Acceptance and commitment therapy for
generalized social anxiety disorder: a pilot study. Behav Modif. (2007) 31:543–
68. doi: 10.1177/0145445507302037
21. Espejo EP, Gorlick A, Castriotta N. Changes in threat- related
cognitions and experiential avoidance in group-based transdiagnostic
CBT for anxiety disorders. J Anxiety Disord. (2017) 46:65–71.
doi: 10.1016/j.janxdis.2016.06.006
22. Eustis EH, Hayes-Skelton SA, Roemer L, Orsillo SM. Reductions in
experiential avoidance as a mediator of change in symptom outcome
and quality of life in acceptance-based behavior therapy and applied
relaxation for generalized anxiety disorder. Behav Res Ther. (2016) 87:188–95.
doi: 10.1016/j.brat.2016.09.012
23. Eustis EH, Cardona N, Nauphal M, Sauer-Zavala S, Rosellini AJ,
Farchione TJ, et al. Experiential avoidance as a mechanism of change
across cognitive-behavioral therapy in a sample of participants with
heterogeneous anxiety disorders. Cognit Ther Res. (2020) 44:275–86.
doi: 10.1007/s10608-019-10063-6
24. Kocovski NL, Fleming JE, Rector NA. Mindfulness and acceptance-based
group therapy for social anxiety disorder: an open trial. Cogn Behav Pract.
(2009) 16:276–89. doi: 10.1016/j.cbpra.2008.12.004
25. Sauer-Zavala S, Boswell JF, Gallagher MW, Bentley KH, Ametaj A, Barlow
DH. The role of negative affectivity and negative reactivity to emotions
in predicting outcomes in the unified protocol for the transdiagnostic
treatment of emotional disorders. Behav Res Ther. (2012) 50:551–7.
doi: 10.1016/j.brat.2012.05.005
26. Kocovski NL, Fleming JE, Hawley LL, Ho M-HR, Antony MM.
Mindfulness and acceptance-based group therapy and traditional cognitive
behavioral group therapy for social anxiety disorder: mechanisms of
change. Behav Res Ther. (2015) 70:11–22. doi: 10.1016/j.brat.2015.
04.005
27. Gámez W, Chmielewski M, Kotov R, Ruggero C, Watson D.
Development of a measure of experiential avoidance: the multidimensional
experiential avoidance questionnaire. Psychol Assess. (2011) 23:692–713.
doi: 10.1037/a0023242
28. Norman SB, Hami Cissell S, Means-Christensen AJ, Stein MB.
Development and validation of an overall anxiety severity and impairment
scale (OASIS). Depress Anxiety. (2006) 23:245–9. doi: 10.1002/da.
20182
29. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining
meaningful change in psychotherapy research. J Consult Clin Psychol. (1991)
59:12–9. doi: 10.1037/0022-006X.59.1.12
30. Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA. Introduction
to SMART designs for the development of adaptive interventions: with
application to weight loss research. Transl Behav Med. (2014) 4:260–74.
doi: 10.1007/s13142-014-0265-0
31. Southward MW, Cassiello-Robbins C, Zelkowitz RL, Rosenthal MZ.
Navigating the new landscape of value-based care: an example of increasing
access, improving quality, and reducing costs using the Unified Protocol.
Behav Therap. (2020) 43:134–7. doi: 10.31234/osf.io/rvbzn
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Southward and Sauer-Zavala. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Psychiatry | www.frontiersin.org 6 December 2020 | Volume 11 | Article 603009
